Drug Discovery World

MAY 6, 2024

As companies move through the phases of development, they benefit from a long-established ecosystem of competency in clinical regulation. So, in this way there is a cross fertilisation from the bigger companies to newer ones.

Drugs 59

Drugs Life Science Gene Editing Gene 59

XTalks

DECEMBER 13, 2023

These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. In 2023, Moderna is poised to achieve sales figures ranging from $6 billion to $8 billion, contingent on the prevailing COVID-19 vaccination rates in the US. vaccine, mRNA-1273.815.

Genetics 111

Genetics Vaccination Vaccine DNA 111

XTalks

AUGUST 18, 2020

Instead of RNA extraction, the Yale test involves use of a reagent that when mixed with a saliva sample and heated for a short period of time, releases the viral genome for subsequent detection with PCR. This is significant because shortages of RNA extraction kits have been a recurrent issue since the beginning of the pandemic.

FDA Approval 90

FDA Approval Reagent RNA Genome 90

Drug Discovery World

AUGUST 8, 2023

According to a report by Deloitte, globally India is the third largest in the world by volume and 11th by value, comprising over 3,000 pharma companies and 10,500 manufacturing facilities 2. The growth and potential in Genome Valley are expressed in the continuous investment in the hub.

Research 52

Research Drugs Genome Genomics 52

Drug Discovery World

OCTOBER 4, 2022

This year, genome engineering company Synthego launched a portfolio of Engineered Cell Librariesnto help improve access to CRISPR-edited cells for direct use in functional screening assays. This year has seen some major deals announced by big pharma companies.

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

Drug Discovery World

JANUARY 26, 2023

Research into HIV blossomed throughout 2022, with ViiV Healthcare’s combination therapy for HIV-1 gaining approval in Japan; and research moving forward towards a one-time treatment for HIV as well as a vaccine. According to research from Deloitte 1 , the average ROI in R&D for global pharma companies fell to just 1.2%

Development 98

Development Drugs Clinical Trials Clinical Trials 98

XTalks

AUGUST 27, 2020

With vaccine trials for COVID-19 ramping up and entering late stages, Johnson & Johnson has announced plans for what will be the largest Phase III trial so far for a vaccine against the novel coronavirus. This is double the enrollment that vaccine makers Moderna and Pfizer have planned for their Phase III trials.

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

XTalks

OCTOBER 15, 2021

The cell line, called HeLa, laid the foundation for many groundbreaking discoveries, including vaccines for the human papilloma virus (HPV) and polio; drugs for HIV and cancers; gene mapping; IVF treatment; and more recently, for crucial COVID-19 research. Fittingly, it was also used to develop the vaccine against cervical cancer.

Vaccination 105

Vaccination Vaccine Gene Mapping Doctors 105

pharmaphorum

SEPTEMBER 7, 2022

Pharma has a great opportunity ahead of it when it comes to conducting representative clinical trials. The industry’s application of mRNA techniques during the pandemic led to the fastest vaccine development in history. But our drug development processes are not perfect. The same is true for Asian and Hispanic populations.

Clinical Trials 95

Clinical Trials Clinical Trials Trials Genetics 95

Drug Discovery World

NOVEMBER 15, 2022

If a pharmaceutical company is racing to identify a new vaccine, for instance, then waiting for three weeks to receive DNA sequences each time can slow down the development process compared to competitors who might have faster timelines.” . The longer the DNA gets, the longer it will take for labs to receive it,” notes Dr Daniels. “If

DNA 98

DNA Drugs Antibody Engineer 98

pharmaphorum

SEPTEMBER 1, 2020

The 2010s have seen the development of innovative new classes of medicines, building on the greater understanding of the body since the genome was first sequenced at the end of the last century. New challenges in an age of innovation.

Medicine 145

Medicine Insulin Pharmacy Drugs 145

pharmaphorum

MARCH 30, 2021

Alexion is a somewhat unique pharma company in that it focuses almost entirely on rare diseases – and although this is an immensely challenging area to operate in, the company’s senior vice president of its international business, Camilla Harder Hartvig, says it provides an unparalleled “sense of mission”.

Genetics 110

Genetics Marketing Development Genome 110

pharmaphorum

DECEMBER 15, 2022

With the bell then tolling within the House of Commons, Brine concluded that prevention and care were critical, and particularly future cancer care – getting ‘upstream’ of symptom-led early diagnosis with genomic medicine, despite the ‘billion ethical questions’ that go alongside that. An extraordinary feat of logistics, he called it.

Life Science 90

Life Science Medicine Clinical Trials Clinical Trials 90

Drug Discovery World

SEPTEMBER 7, 2022

The incredible speeds at which Covid-19 vaccines were successfully developed and brought to market highlighted to the world and the industry that lengthy development timelines aren’t always assured. The pandemic also highlighted the need for life sciences companies to adopt technologies that can help them work more efficiently.

Research 52

Research Scientist Clinical Trials Clinical Trials 52

Pharmaceutical Technology

MARCH 20, 2023

Pharma companies and world health stand to benefit from new technologies, but it’s a tough time to be an investor – and an even tougher one for firms seeking investment. The mRNA technology that enabled the largest and fastest vaccine rollout in history is the tip of the innovation iceberg.

Gene Therapy 225

Gene Therapy Genome Genomics Gene 225